Fusion protein having enhanced in vivo erythropoietin activity
CA 2400908 C · Owner: Cj Healthcare Corporation · Inventors: Oh, Myung-Suk; Park, Ji-Sook; Chung, Bo-Sup
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Provided is a fusion protein comprising at its carboxy terminal of human erythropoietin (EPO) a mutant having one to four amino acid substitutions in the carboxy terminal peptide (CTP) fragment of a human chorionic gonadotropin (HCG) .beta. subunit for increasing an in vivo half-life activity of EPO. The in vivo half- life can be greatly elongated while retaining the intrinsic activity of the EPO without increasing the sugar chain content.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 29, 2002 and granted April 12, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 29, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 29, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.